Measure of adherence to direct-acting antivirals as a predictor of the effectiveness of hepatitis C treatment

被引:8
|
作者
Campos Fernandez de Sevilla, Maria Angeles [1 ]
Gallego Ubeda, Marta [1 ]
Tovar Pozo, Maria [1 ]
Garcia-Cabrera, Emilio [2 ]
Monje Garcia, Beatriz [1 ]
Tutau Gomez, Federico [3 ]
Delgado Tellez de Cepeda, Laura [3 ]
Iglesias-Peinado, Irene [4 ]
机构
[1] Hosp Univ Henares, Pharm Dept, Clin Pharm, Madrid, Spain
[2] Delos Clin, Seville, Spain
[3] Hosp Univ Henares, Pharm Dept, PharmD & Clin Pharm, Madrid, Spain
[4] Univ Complutense Madrid, Fac Pharm, PharmD, Madrid, Spain
关键词
Adherence; Antivirals; Chronic hepatitis C; Infectious diseases; Spain; HIV-INFECTED PATIENTS; COHORT; METAANALYSIS; INTERFERON; SOFOSBUVIR; RIBAVIRIN; VALIDITY; THERAPY;
D O I
10.1007/s11096-019-00917-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background Adherence to direct-acting antivirals could be a predictor response to these treatments in hepatitis C. Objective To assess the ability of three methods of measuring adherence to direct-acting antivirals [pill counts, pharmacy dispensing record and Simplified Medication Adherence Questionnaire (SMAQ)] as predictors of their effectiveness. Setting Study conducted by the pharmacy department of the hospital. Methods: A retrospective study was performed. Patients >= 18 years with hepatitis C that started and completed treatment with direct-acting antivirals between the 1st-April-2015 and 28st-February-2016 were enrolled. To evaluate the predictive ability to obtain a response to treatment, Chi squared test, Mann-Whitney-U test and ROC-curves were used. Main outcome measure Adherence to antivirals was assessed by three methods and response to treatment, which was defined as obtaining a viral load of hepatitis C virus <= 15UI/ml at week 12 after the end of treatment. Results 128 patients were enrolled. The overall average adherence obtained with SMAQ (99.09%) was similar to the pill counts (96.40%, p = 0.043) and pharmacy dispensing record (91.10%, p = 0.02). There was no correlation between the percentage of patients considered as adherent by SMAQ (99.09%) and the achievement of response to treatment (96.40%, p = 0.999). The ROC-curve obtained for the pill count method shows a global area under the curve of 0.53. For pharmacy dispensing record method, patients with an adherence <= 66.66% have a high probability of not achieving response (sensitivity and specificity of 79.00% and 100.00%, respectively). Conclusions Pharmacy dispensing record is shown as the best indicator of adherence to predict therapeutic failure in our study.
引用
收藏
页码:1545 / 1554
页数:10
相关论文
共 50 条
  • [41] Impact of treatment with direct-acting antivirals on anxiety and depression in chronic hepatitis C
    Gallach, Marta
    Vergara, Mercedes
    Pedro da Costa, Joao
    Miquel, Mireia
    Casas, Meritxell
    Sanchez-Delgado, Jordi
    Dalmau, Blai
    Rudi, Nuria
    Parra, Isabel
    Monllor, Teresa
    Sanchez-Lloansi, Meritxell
    Dosal, Angelina
    Valero, Oliver
    Calvet, Xavier
    PLOS ONE, 2018, 13 (12):
  • [42] Effectiveness of direct: Acting antivirals for the treatment of viral hepatitis C in Rwanda
    Serumondo, Janvier
    Penkunas, Michael
    Ngwije, Alida
    Remera, Eric
    Liu, Carol
    Sebuhoro, Dieudonne
    Umutesi, Justine
    Musanabaganwa, Clarisse
    Karame, Prosper
    Musengimana, Gentille
    Ntihabose, Corneille Killy
    Umuraza, Sabine
    Mulindabigwi, Augustin
    Niyikora, Julienne
    Mugeni, Soline
    Ntirenganya, Cyprien
    Kiromera, Athanase
    Nsanzimana, Sabin
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E337 - E337
  • [43] Future of hepatitis C therapy: development of direct-acting antivirals
    Dore, Gregory J.
    Matthews, Gail V.
    Rockstroh, Juergen
    CURRENT OPINION IN HIV AND AIDS, 2011, 6 (06) : 508 - 513
  • [44] Hepatitis C virus resistance to the new direct-acting antivirals
    Esposito, Isabella
    Trinks, Julieta
    Soriano, Vicente
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (10) : 1197 - 1209
  • [45] Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway
    Torbjørn Wisløff
    Richard White
    Olav Dalgard
    Ellen J. Amundsen
    Hinta Meijerink
    Astrid Louise Løvlie
    Hilde Kløvstad
    PharmacoEconomics, 2018, 36 : 591 - 601
  • [46] Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway
    Wisloff, Torbjorn
    White, Richard
    Dalgard, Olav
    Amundsen, Ellen J.
    Meijerink, Hinta
    Lovlie, Astrid Louise
    Klovstad, Hilde
    PHARMACOECONOMICS, 2018, 36 (05) : 591 - 601
  • [47] Cardiometabolic effects of direct-acting antivirals in patients with hepatitis C
    Neokosmidis, Georgios
    Protopapas, Adonis A.
    Stogiannou, Dimitrios
    Filippidis, Athanasios
    Tziomalos, Konstantinos
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2023, 46 (01): : 58 - 66
  • [48] Comments on Cochrane Review on Direct-Acting Antivirals for Hepatitis C
    Lok, Anna S.
    Chung, Raymond T.
    Vargas, Hugo E.
    Kim, Arthur Y.
    Naggie, Susanna
    Powderly, William G.
    HEPATOLOGY, 2017, 66 (04) : 1016 - 1019
  • [49] Direct-acting antivirals for children and adolescents with chronic hepatitis C
    Indolfi, Giuseppe
    Serranti, Daniele
    Resti, Massimo
    LANCET CHILD & ADOLESCENT HEALTH, 2018, 2 (04): : 298 - 304
  • [50] COST-EFFECTIVENESS OF DIRECT-ACTING ANTIVIRALS FOR CHRONIC HEPATITIS C TREATMENT-NAIVE PATIENTS IN CHINA
    Wei, X.
    Feng, Y.
    Yang, L.
    VALUE IN HEALTH, 2019, 22 : S197 - S198